B型肝炎治療ガイドライン(第1.1版)

• Material Type: 記事
• Title: B型肝炎治療ガイドライン(第1.1版)
• Author/Editor: 日本肝臓学会肝炎診療ガイドライン作成委員会
• Author Heading: 日本肝臓学会肝炎診療ガイドライン作成委員会
• Alternative Title: Guidelines for the management of hepatitis B virus infection
• Periodical title: 肝臓
• No. or year of volume/issue: 54(6):2013.6
• Volume: 54
• Issue: 6
• Pages: 402-472
• Publication date of volume/issue (W3CDTF): 2013-06
• ISSN (Periodical Title): 0451-4203
• ISSN-L (Periodical Title): 0451-4203
• Publication (Periodical Title): 東京 : 日本肝臓学会
• Place of Publication (Country Code): JP
• Text Language Code: jpn
• Subject Heading: B型肝炎; ガイドライン; 核酸アナログ; インターフェロン; エンテカビル; hepatitis B; guidelines; nucleos(t)ide analogs; interferon; entecavir
• NDLC: ZS21
• Target Audience: 一般
• Holding library: 国立国会図書館
• Call No.: Z19-130
• Data Provider (Database): 国立国会図書館 : 国立国会図書館雑誌記事索引; https://ndlsearch.ndl.go.jp
• Bibliographic ID (NDL): 024632171; http://id.ndl.go.jp/bib/024632171
• Bibliographic Record Category (NDL): 632

• Summary, etc.: Two male patients with liver dysfunction were admitted to our hospital and diagnosed to acute hepatitis E by detection of IgA class anti-Hepatitis E virus antibody and Hepatitis E virus (HEV) RNA. Following admission, liver dyfunction was improved by conservative treatment. Although the infection route of HEV was unknown, analysis of HEV genome sequence revealed that the HEV isolated from the two cases belonged to genotype 3 and had homology. So we considered that the HEV strains were presumed to be indigenous to Kitakyushu. Because fulminant hepatitis due to HEV has been reported, even in nonepidemic area, we need to pay attention to acute hepatitis E in treatment of patients with liver dysfunction of unknown origin.<br>
• DOI: 10.2957/kanzo.54.399
• Access Restrictions: インターネット公開
• Data Provider (Database): 科学技術振興機構 : J-STAGE; http://www.jstage.jst.go.jp

• Summary, etc.: Two male patients with liver dysfunction were admitted to our hospital and diagnosed to acute hepatitis E by detection of IgA class anti-Hepatitis E virus antibody and Hepatitis E virus (HEV) RNA. Following admission, liver dyfunction was improved by conservative treatment. Although the infection route of HEV was unknown, analysis of HEV genome sequence revealed that the HEV isolated from the two cases belonged to genotype 3 and had homology. So we considered that the HEV strains were presumed to be indigenous to Kitakyushu. Because fulminant hepatitis due to HEV has been reported, even in nonepidemic area, we need to pay attention to acute hepatitis E in treatment of patients with liver dysfunction of unknown origin.<br>
• DOI: 10.2957/kanzo.54.399; https://doi.org/10.2957/kanzo.54.399; 10.2957/kanzo.54.402; https://doi.org/10.2957/kanzo.54.402
• Related Material (URI): http://id.ndl.go.jp/bib/024632171; https://ndlsearch.ndl.go.jp/books/R000000004-I024632171; http://id.ndl.go.jp/bib/024632149; https://ndlsearch.ndl.go.jp/books/R000000004-I024632149; https://www.jstage.jst.go.jp/article/kanzo/54/6/54_402/_pdf; https://www.jstage.jst.go.jp/article/kanzo/54/6/54_399/_pdf; https://search.jamas.or.jp/link/ui/2013286354
• Has Version: Guidelines for the management of hepatitis B virus infection; https://cir.nii.ac.jp/crid/2120307889961334912
• Is Referenced By: B型肝炎治療ガイドライン・C型肝炎治療ガイドライン; https://cir.nii.ac.jp/crid/1390001206450114176; 急性肝不全：わが国における課題; https://cir.nii.ac.jp/crid/1390282679771629056; 1．免疫抑制剤使用時の肝炎ウイルス再活性化; https://cir.nii.ac.jp/crid/1390282681423844480
• References: Risk of hepatitis B reactivation in patients treated with tumor necrosis factor‐α inhibitors; https://cir.nii.ac.jp/crid/1050282813890907648; Measurement of hepatitis B virus core‐related antigen is valuable for identifying patients who are at low risk of lamivudine resistance; https://cir.nii.ac.jp/crid/1050282813891887616; Mortality secondary to fulminant hepatic failure in patients with prior resolution of hepatitis B virus infection in Japan; https://cir.nii.ac.jp/crid/1050282813895513856; Efficacy of lamivudine for preventing hepatocellular carcinoma in chronic hepatitis B: A multicenter retrospective study of 2795 patients; https://cir.nii.ac.jp/crid/1050564288868599808; Hepatitis B virus strains of subgenotype A2 with an identical sequence spreading rapidly from the capital region to all over Japan in patients with acute hepatitis B; https://cir.nii.ac.jp/crid/1050568772239857920; Prospective study of reactivation of hepatitis B virus in patients with rheumatoid arthritis who received immunosuppressive therapy: evaluation of both HBsAg-positive and HBsAg-negative cohorts; https://cir.nii.ac.jp/crid/1360002215326388096; Four-year study of lamivudine and adefovir combination therapy in lamivudine-resistant hepatitis B patients: influence of hepatitis B virus genotype and resistance mutation pattern; https://cir.nii.ac.jp/crid/1360002218199423872; Prevention of hepatitis B virus reactivation in patients receiving immunosuppressive therapy or chemotherapy; https://cir.nii.ac.jp/crid/1360002218323019648; Long-term use of entecavir in nucleoside-naïve Japanese patients with chronic hepatitis B infection; https://cir.nii.ac.jp/crid/1360004232280670208; A nationwide survey of hepatitis E virus infection in the general population of Japan; https://cir.nii.ac.jp/crid/1360011143641817472; High Levels of Hepatitis B Surface Antigen Increase Risk of Hepatocellular Carcinoma in Patients With Low HBV Load; https://cir.nii.ac.jp/crid/1360011143664533504; Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2008 update; https://cir.nii.ac.jp/crid/1360011143713081984; Sequential treatment with lamivudine and interferon- monotherapies in hepatitis B e antigen-negative Chinese patients and its suppression of lamivudine-resistant mutations; https://cir.nii.ac.jp/crid/1360011143738569216; Risks of immunosuppressive therapies including biologic agents in patients with rheumatic diseases and co-existing chronic viral infections; https://cir.nii.ac.jp/crid/1360011143909775232; Severe lactic acidosis during treatment of chronic hepatitis B with entecavir in patients with impaired liver function†; https://cir.nii.ac.jp/crid/1360011143924207360; Long-Term Follow-up of HBeAg-Positive Patients Treated with Interferon Alfa for Chronic Hepatitis B; https://cir.nii.ac.jp/crid/1360011144139270272; Distribution of hepatitis B viral genotypes and mutations in the core promoter and precore regions in acute forms of liver disease in patients from Chiba, Japan; https://cir.nii.ac.jp/crid/1360011144295606272; Determinants for hepatitis B e antigen clearance in chronic type B hepatitis; https://cir.nii.ac.jp/crid/1360011144305460864; Clearance of hepatitis B surface antigen during long-term nucleot(s)ide analog treatment in chronic hepatitis B: results from a nine-year longitudinal study; https://cir.nii.ac.jp/crid/1360011144393011456; The treatment effect of alpha interferon in chronic hepatitis B is independent of pre-treatment variables. Results based on individual patient data from 10 clinical controlled trials; https://cir.nii.ac.jp/crid/1360011144460571392; Incomplete Reversibility of Tenofovir-Related Renal Toxicity in HIV-Infected Men; https://cir.nii.ac.jp/crid/1360011144528710016; The interferon response circuit: Induction and suppression by pathogenic viruses; https://cir.nii.ac.jp/crid/1360011144622499456; Hepatitis B Virus Core-Related Antigens as Markers for Monitoring Chronic Hepatitis B Infection; https://cir.nii.ac.jp/crid/1360011144832994304; Pharmacokinetics of Peginterferons; https://cir.nii.ac.jp/crid/1360011145061790080; Two-Year Assessment of Entecavir Resistance in Lamivudine-Refractory Hepatitis B Virus Patients Reveals Different Clinical Outcomes Depending on the Resistance Substitutions Present; https://cir.nii.ac.jp/crid/1360011145278565888; Polymorphisms Near IL28B and Serologic Response to Peginterferon in HBeAg-Positive Patients With Chronic Hepatitis B; https://cir.nii.ac.jp/crid/1360011145281656192; Hepatitis B Virus Strains with Mutations in the Core Promoter in Patients with Fulminant Hepatitis; https://cir.nii.ac.jp/crid/1360011145646189440; Long-term Therapy With Adefovir Dipivoxil for HBeAg-Negative Chronic Hepatitis B for up to 5 Years; https://cir.nii.ac.jp/crid/1360011145649978368; Spontaneous hepatitis B e antigen to antibody seroconversion and reversion in Chinese patients with chronic hepatitis B virus infection; https://cir.nii.ac.jp/crid/1360011145712036224; Factors That Predict Response of Patients With Hepatitis B e Antigen–Positive Chronic Hepatitis B to Peginterferon-Alfa; https://cir.nii.ac.jp/crid/1360011145778382720; Clinical and virological effects of long‐term (over 5 years) lamivudine therapy; https://cir.nii.ac.jp/crid/1360011145809930368; Kinetics and Risk of De Novo Hepatitis B Infection in HBsAg–Negative Patients Undergoing Cytotoxic Chemotherapy; https://cir.nii.ac.jp/crid/1360011145818484992; Hepatitis B e antigen seroconversion after lamivudine therapy is not durable in patients with chronic hepatitis B in Korea; https://cir.nii.ac.jp/crid/1360011146108183936; Durability of HBeAg seroconversion following antiviral therapy for chronic hepatitis B: relation to type of therapy and pretreatment serum hepatitis B virus DNA and alanine aminotransferase; https://cir.nii.ac.jp/crid/1360011146342877056; Chronic HBV infection with persistently normal ALT b. not to treat; https://cir.nii.ac.jp/crid/1360011146355102464; Management of HBV infection in Japan; https://cir.nii.ac.jp/crid/1360011146546429184; Long-Term Lamivudine Therapy Reduces the Risk of Long-Term Complications of Chronic Hepatitis B Infection even in Patients without Advanced Disease; https://cir.nii.ac.jp/crid/1360016866459014144; Long-term Therapy With Tenofovir Is Effective for Patients Co-Infected With Human Immunodeficiency Virus and Hepatitis B Virus; https://cir.nii.ac.jp/crid/1360292618617461248; The influence of hepatitis B virus genotype on the development of lamivudine resistance during long-term treatment; https://cir.nii.ac.jp/crid/1360292619051672448; Predictors of HBeAg loss after lamivudine treatment for chronic hepatitis B; https://cir.nii.ac.jp/crid/1360292619158254464; Wild-type and e antigen-minus hepatitis B viruses and course of chronic hepatitis.; https://cir.nii.ac.jp/crid/1360292619263261312; Serological detection of hepatitis B virus genotypes by ELISA with monoclonal antibodies to type-specific epitopes in the preS2-region product; https://cir.nii.ac.jp/crid/1360292619315502592; Acute exacerbation and hepatitis B virus clearance after emergence of YMDD motif mutation during lamivudine therapy; https://cir.nii.ac.jp/crid/1360292619502818560; Peginterferon alpha-2b plus adefovir induce strong cccDNA decline and HBsAg reduction in patients with chronic hepatitis B; https://cir.nii.ac.jp/crid/1360292619740861952; Lamivudine-to-entecavir switching treatment in type B chronic hepatitis patients without evidence of lamivudine resistance; https://cir.nii.ac.jp/crid/1360292619854642048; Hepatitis B Virus Infection — Natural History and Clinical Consequences; https://cir.nii.ac.jp/crid/1360292619950743808; Administration of Interferon at Night May Increase its Therapeutic Index; https://cir.nii.ac.jp/crid/1360292620078320000; A prospective and comparative cohort study on efficacy and drug resistance during long‐term lamivudine treatment for various stages of chronic hepatitis B and cirrhosis; https://cir.nii.ac.jp/crid/1360292620127884032; Mutations of polymerase, precore and core promoter gene in hepatitis B virus during 5-year lamivudine therapy; https://cir.nii.ac.jp/crid/1360292620475452928; Durability of Peginterferon Alfa-2B Treatment at 5 Years in Patients With Hepatitis B E Antigen–Positive Chronic Hepatitis B; https://cir.nii.ac.jp/crid/1360292620765585152; Long-term outcome after spontaneous HBeAg seroconversion in patients with chronic hepatitis B; https://cir.nii.ac.jp/crid/1360292621609837696; Changes in viral loads of lamivudine‐resistant mutants during entecavir therapy; https://cir.nii.ac.jp/crid/1360298342885794688; Clinical course and predictive factors of virological response in long‐term lamivudine plus adefovir dipivoxil combination therapy for lamivudine‐resistant chronic hepatitis B patients; https://cir.nii.ac.jp/crid/1360567180140544000; Recommendation of lamivudine‐to‐entecavir switching treatment in chronic hepatitis B responders: Randomized controlled trial; https://cir.nii.ac.jp/crid/1360567185710649216; Classifying Hepatitis B Virus Genotypes; https://cir.nii.ac.jp/crid/1360574093510304128; Long–Term Follow–Up of Interferon Alfa Treatment in Chinese Patients With Chronic Hepatitis B Infection: the Effect on Hepatitis B E Antigen Seroconversion and the Development of Cirrhosis–Related Complications; https://cir.nii.ac.jp/crid/1360574093658744320; Combination therapy of lamivudine and adefovir in Japanese patients with chronic hepatitis B; https://cir.nii.ac.jp/crid/1360574093690424704; Nephrotoxicity, including acquired Fanconi’s syndrome, caused by adefovir dipivoxil - is there a safe dose?; https://cir.nii.ac.jp/crid/1360574094124252672; Management of Chronic Hepatitis B: Status and Challenges beyond Treatment Guidelines; https://cir.nii.ac.jp/crid/1360574094327386624; Lamivudine treatment for decompensated cirrhosis resulting from chronic hepatitis B; https://cir.nii.ac.jp/crid/1360574094377218944; Treatment of HBeAg‐negative chronic hepatitis B with pegylated interferon; https://cir.nii.ac.jp/crid/1360574094499791104; The role of hepatitis B virus integrations in the pathogenesis of human hepatocellular carcinoma; https://cir.nii.ac.jp/crid/1360574094518820352; Prediction of Liver-Related Events Using Fibroscan in Chronic Hepatitis B Patients Showing Advanced Liver Fibrosis; https://cir.nii.ac.jp/crid/1360574094538374144; Lamivudine for the Prevention of Hepatitis B Virus Reactivation in Hepatitis B s-Antigen Seropositive Cancer Patients Undergoing Cytotoxic Chemotherapy; https://cir.nii.ac.jp/crid/1360574094568536064; Hepatitis B Virus Reactivation in Lymphoma Patients With Prior Resolved Hepatitis B Undergoing Anticancer Therapy With or Without Rituximab; https://cir.nii.ac.jp/crid/1360574094632531456; Efficacy of 6-month interferon therapy in chronic hepatitis B virus infection in Japan; https://cir.nii.ac.jp/crid/1360574094762954752; Two types of drug-resistant hepatitis B viral strains emerging alternately and their susceptibility to combination therapy with entecavir and adefovir; https://cir.nii.ac.jp/crid/1360574094986066304; Factors associated with the virological response of lamivudine-resistant hepatitis B virus during combination therapy with adefovir dipivoxil plus lamivudine; https://cir.nii.ac.jp/crid/1360574095109767040; REVERSE SEROCONVERSION OF HEPATITIS B AFTER ALLOGENEIC BONE MARROW TRANSPLANTATION; https://cir.nii.ac.jp/crid/1360574095261891072; Case–control study for the identification of virological factors associated with fulminant hepatitis B; https://cir.nii.ac.jp/crid/1360574095278681216; Pre-S2 defective hepatitis B virus infection in patients with fulminant hepatitis; https://cir.nii.ac.jp/crid/1360574095554786560; Risk of Hepatocellular Carcinoma Across a Biological Gradient of Serum Hepatitis B Virus DNA Level; https://cir.nii.ac.jp/crid/1360574095571862528; Outcome of renal transplantation in hepatitis B surface antigen‐positive patients after introduction of lamivudine†; https://cir.nii.ac.jp/crid/1360574095592769792; Prediction of Sustained Response to Peginterferon Alfa-2b for Hepatitis B e Antigen–Positive Chronic Hepatitis B Using on-Treatment Hepatitis B Surface Antigen Decline; https://cir.nii.ac.jp/crid/1360574095600485760; Hepatitis B virus surface antigen levels: A guide to sustained response to peginterferon alfa-2a in HBeAg-negative chronic hepatitis B # †; https://cir.nii.ac.jp/crid/1360574095786837760; The long-term outcome of interferon-α treated and untreated patients with HBeAg-negative chronic hepatitis B; https://cir.nii.ac.jp/crid/1360574095938111360; Evolution of Hepatitis B Virus Polymerase Gene Mutations in Hepatitis B E Antigen-Negative Patients Receiving Lamivudine Therapy; https://cir.nii.ac.jp/crid/1360574096117834880; Predictive Factors Associated with the Progression to Hepatic Failure Caused by Lamivudine-Resistant HBV; https://cir.nii.ac.jp/crid/1360574096146993920; Entecavir and interferon-α sequential therapy in Japanese patients with hepatitis B e antigen-positive chronic hepatitis B; https://cir.nii.ac.jp/crid/1360848656190200320; Combination of hepatitis B viral antigens and DNA for prediction of relapse after discontinuation of nucleos(t)ide analogs in patients with chronic hepatitis B; https://cir.nii.ac.jp/crid/1360848660687481088; Interferon for treatment of breakthrough infection with hepatitis B virus mutants developing during long-term lamivudine therapy; https://cir.nii.ac.jp/crid/1360855568772292096; Indications for therapy in hepatitis B #; https://cir.nii.ac.jp/crid/1360855568785381376; Response to long‐term lamivudine treatment in patients infected with hepatitis B virus genotypes A, B, and C; https://cir.nii.ac.jp/crid/1360855568939122560; The long‐term effect of treatment with interferon‐α2a in chronic hepatitis B; https://cir.nii.ac.jp/crid/1360855568999434240; Comparison of different immunoprophylaxis regimens after liver transplantation with hepatitis B core antibody–positive donors: A systematic review; https://cir.nii.ac.jp/crid/1360855569102620800; Prognosis following spontaneous HBsAg seroclearance in chronic hepatitis B patients with or without concurrent infection; https://cir.nii.ac.jp/crid/1360855569222448896; Efficacy of Lamivudine Therapy and Factors Associated with Emergence of Resistance in Chronic Hepatitis B Virus Infection in Japan; https://cir.nii.ac.jp/crid/1360855569278282752; Changes in Serum Levels of HBV DNA and Alanine Aminotransferase Determine Risk for Hepatocellular Carcinoma; https://cir.nii.ac.jp/crid/1360855569486714880; Hepatic events after bone marrow transplantation in patients with hepatitis B infection: a case controlled study; https://cir.nii.ac.jp/crid/1360855569788364544; Emergence and takeover of YMDD motif mutant hepatitis B virus during long-term lamivudine therapy and re-takeover by wild type after cessation of therapy; https://cir.nii.ac.jp/crid/1360855569790044032; Outcome of Hepatitis B e Antigen–Negative Chronic Hepatitis B on Long-Term Nucleos(t)ide Analog Therapy Starting With Lamivudine *; https://cir.nii.ac.jp/crid/1360855569792063744; A randomized controlled trial of pegylated interferon-α2a plus adefovir dipivoxil for hepatitis B e antigen-negative chronic hepatitis B; https://cir.nii.ac.jp/crid/1360855569958216448; Long-term follow-up of chronic hepatitis B patients treated with interferon alfa; https://cir.nii.ac.jp/crid/1360855570155109632; A Personalized Approach to Optimize Hepatitis B Treatment in Treatment-naive Patients; https://cir.nii.ac.jp/crid/1360855570455106304; Lamivudine treatment is associated with improved survival in fulminant hepatitis B; https://cir.nii.ac.jp/crid/1360855570526736384; Sustained response to peginterferon alfa-2a (40 kD) with or without lamivudine in Asian patients with HBeAg-positive and HBeAg-negative chronic hepatitis B; https://cir.nii.ac.jp/crid/1360855570677186176; Tenofovir disoproxil fumarate rescue therapy following failure of both lamivudine and adefovir dipivoxil in chronic hepatitis B; https://cir.nii.ac.jp/crid/1360855571291719680; Elastography for the diagnosis of severity of fibrosis in chronic liver disease: A meta-analysis of diagnostic accuracy; https://cir.nii.ac.jp/crid/1360855571515144064; Measurement of hepatitis B virus core-related antigen as predicting factor for relapse after cessation of lamivudine therapy for chronic hepatitis B virus infection; https://cir.nii.ac.jp/crid/1361137043407319168; Hepatitis B surface antigen: association with sustained response to peginterferon alfa-2a in hepatitis B e antigen-positive patients; https://cir.nii.ac.jp/crid/1361137043631007872; Low serum level of hepatitis B core‐related antigen indicates unlikely reactivation of hepatitis after cessation of lamivudine therapy; https://cir.nii.ac.jp/crid/1361137043680706944; Clearance of Hepatitis B Surface Antigen and Risk of Hepatocellular Carcinoma in A Cohort Chronically Infected With Hepatitis B Virus; https://cir.nii.ac.jp/crid/1361137043868284800; Outcome of anti-HBe positive chronic hepatitis B in alpha-interferon treated and untreated patients: a long term cohort study; https://cir.nii.ac.jp/crid/1361137043926339584; Risk assessment for the development of hepatocellular carcinoma: According to on-treatment viral response during long-term lamivudine therapy in hepatitis B virus-related liver disease; https://cir.nii.ac.jp/crid/1361137043938897152; Acute exacerbations in Chinese patients with chronic hepatitis B virus (HBV) infection; https://cir.nii.ac.jp/crid/1361137043982137088; Non‐invasive assessment of liver fibrosis by stiffness measurement in patients with chronic hepatitis B; https://cir.nii.ac.jp/crid/1361137044428412160; 917 ON-TREATMENT MONITORING OF HBsAg LEVELS TO PREDICT RESPONSE TO PEGINTERFERON ALFA-2A IN PATIENTS WITH HBeAg-POSITIVE CHRONIC HEPATITIS B; https://cir.nii.ac.jp/crid/1361137044973470208; Sero-clearance of hepatitis B surface antigen in chronic carriers does not necessarily imply a good prognosis; https://cir.nii.ac.jp/crid/1361137045202833792; Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-naïve patients is rare through 5 years of therapy #; https://cir.nii.ac.jp/crid/1361137045436302080; 69 NEPTUNE STUDY: ON-TREATMENT HBSAG LEVEL ANALYSIS CONFIRMS PREDICTION OF RESPONSE OBSERVED IN PHASE 3 STUDY OF PEGINTERFERON ALFA-2A IN HBEAG-POSITIVE PATIENTS; https://cir.nii.ac.jp/crid/1361137045488590080; Sensitive Enzyme Immunoassay for Hepatitis B Virus Core-Related Antigens and Their Correlation to Virus Load; https://cir.nii.ac.jp/crid/1361137045509395840; Factors contributing to antiviral effect of adefovir dipivoxil therapy added to ongoing lamivudine treatment in patients with lamivudine-resistant chronic hepatitis B; https://cir.nii.ac.jp/crid/1361137045751741952; Pretreatment symptoms and dosing regimen predict side‐effects of interferon therapy for hepatitis C; https://cir.nii.ac.jp/crid/1361137045752205696; Pathogenesis of hepatitis B virus—related hepatocellular carcinoma: Old and new paradigms; https://cir.nii.ac.jp/crid/1361137045809487360; Distribution of Hepatitis B Virus Genotypes among Patients with Chronic Infection in Japan Shifting toward an Increase of Genotype A; https://cir.nii.ac.jp/crid/1361137046000450560; EASL Clinical Practice Guidelines: Management of chronic hepatitis B virus infection; https://cir.nii.ac.jp/crid/1361137046063566976; Chronic hepatitis B in children after e antigen seroclearance: Final report of a 29-year longitudinal study; https://cir.nii.ac.jp/crid/1361137046139776768; Spontaneous clearance of high-titer serum HBV DNA and risk of hepatocellular carcinoma in a Chinese population; https://cir.nii.ac.jp/crid/1361137046318922752; Loss of HBsAg antigen during treatment with entecavir or lamivudine in nucleoside-naïve HBeAg-positive patients with chronic hepatitis B*; https://cir.nii.ac.jp/crid/1361137046531124096; Clinical Pharmacokinetics of Interferons; https://cir.nii.ac.jp/crid/1361418518953319040; Efficacy and safety of entecavir in lamivudine‐refractory patients with chronic hepatitis B: Randomized controlled trial in Japanese patients; https://cir.nii.ac.jp/crid/1361418519376555392; Updated Definitions of Healthy Ranges for Serum Alanine Aminotransferase Levels; https://cir.nii.ac.jp/crid/1361418519485062272; Hepatitis B virus (HBV) reactivation with immunosuppressive therapy in rheumatic diseases: assessment and preventive strategies; https://cir.nii.ac.jp/crid/1361418519546669184; Interferon therapy for flare-up of hepatitis B virus infection after emergence of lamivudine-induced YMDD motif mutant; https://cir.nii.ac.jp/crid/1361418519998895360; Sustained Response of Hepatitis B e Antigen-Negative Patients 3 Years After Treatment with Peginterferon Alfa-2a; https://cir.nii.ac.jp/crid/1361418520015945216; Predicting Relapse after Cessation of Lamivudine Monotherapy for Chronic Hepatitis B Virus Infection; https://cir.nii.ac.jp/crid/1361418520100715520; Safety and efficacy of lamivudine in patients with severe acute or fulminant hepatitis B, a multicenter experience; https://cir.nii.ac.jp/crid/1361418520105656960; Long-Term Efficacy of Tenofovir Monotherapy for Hepatitis B Virus-Monoinfected Patients After Failure of Nucleoside/Nucleotide Analogues; https://cir.nii.ac.jp/crid/1361418520342876800; Adding-on versus switching-to adefovir therapy in lamivudine-resistant HBeAg-negative chronic hepatitis B; https://cir.nii.ac.jp/crid/1361418520578231424; The Study of Efficacy of Lamivudine in Patients with Severe Acute Hepatitis B; https://cir.nii.ac.jp/crid/1361418521042320640; Entecavir treatment reduces hepatic events and deaths in chronic hepatitis B patients With liver cirrhosis; https://cir.nii.ac.jp/crid/1361418521194006912; Antiviral drug-resistant HBV; https://cir.nii.ac.jp/crid/1361699993483932160; A Comparison of Entecavir and Lamivudine for HBeAg-Positive Chronic Hepatitis B; https://cir.nii.ac.jp/crid/1361699993865715200; Measurement of Liver Elasticity with Acoustic Radiation Force Impulse (ARFI) Technology: An Alternative Noninvasive Method for Staging Liver Fibrosis in Viral Hepatitis; https://cir.nii.ac.jp/crid/1361699994115058560; Influence of genotypes and precore mutations on fulminant or chronic outcome of acute hepatitis B virus infection; https://cir.nii.ac.jp/crid/1361699994175591680; A partially overlapping treatment course with lamivudine and interferon in hepatitis B e antigen‐negative chronic hepatitis B; https://cir.nii.ac.jp/crid/1361699994191585152; Natural History of Hepatitis B Virus Infection in Renal Transplant Recipients-A Fifteen-Year Follow-Up; https://cir.nii.ac.jp/crid/1361699994489652608; Predominance of genotype A HBV in an HBV‐HIV‐1 dually positive population compared with an HIV‐1–negative counterpart in Japan; https://cir.nii.ac.jp/crid/1361699994616654336; A Randomized, Controlled Trial of Interferon Alfa-2b Alone and after Prednisone Withdrawal for the Treatment of Chronic Hepatitis B; https://cir.nii.ac.jp/crid/1361699994963641728; A revisit of prophylactic lamivudine for chemotherapy-associated hepatitis B reactivation in non-Hodgkin's lymphoma: A randomized trial; https://cir.nii.ac.jp/crid/1361699994988635904; Early serum HBsAg drop: A strong predictor of sustained virological response to pegylated interferon alfa-2a in HBeAg-negative patients #; https://cir.nii.ac.jp/crid/1361699995084873728; Initial Virological Response and Viral Mutation with Adefovir Dipivoxil Added to Ongoing Lamivudine Therapy in Lamivudine-Resistant Chronic Hepatitis B; https://cir.nii.ac.jp/crid/1361699995750607360; Seroconversion from Hepatitis B e Antigen to Antibody in Chronic Type B Hepatitis; https://cir.nii.ac.jp/crid/1361699995800627840; Virologic response and resistance to adefovir in patients with chronic hepatitis B; https://cir.nii.ac.jp/crid/1361699995829570176; Hepatitis B e antigen-negative chronic hepatitis B; https://cir.nii.ac.jp/crid/1361699995992128384; Hepatitis B virus reactivation and alemtuzumab therapy; https://cir.nii.ac.jp/crid/1361699996066039424; Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial; https://cir.nii.ac.jp/crid/1361699996121626240; Predicting Cirrhosis Risk Based on the Level of Circulating Hepatitis B Viral Load; https://cir.nii.ac.jp/crid/1361699996200230144; Chronic hepatitis B: Update 2009 #; https://cir.nii.ac.jp/crid/1361981468351019136; Histological changes in liver biopsies after one year of lamivudine treatment in patients with chronic hepatitis B infection; https://cir.nii.ac.jp/crid/1361981468461461760; Interferon decreases hepatocellular carcinogenesis in patients with cirrhosis caused by the hepatitis B virus; https://cir.nii.ac.jp/crid/1361981468526192896; Renal dysfunction in chronic hepatitis B patients treated with adefovir dipivoxil #; https://cir.nii.ac.jp/crid/1361981468553681664; Hepatitis B virus reactivation with clinical flare in allogeneic stem cell transplants with chronic graft-versus-host disease; https://cir.nii.ac.jp/crid/1361981468721560192; Mutations in the Precore Region of Hepatitis B Virus DNA in Patients with Fulminant and Severe Hepatitis; https://cir.nii.ac.jp/crid/1361981468924869888; Peginterferon Alfa-2a Alone, Lamivudine Alone, and the Two in Combination in Patients with HBeAg-Negative Chronic Hepatitis B; https://cir.nii.ac.jp/crid/1361981468928467712; Spatial and chronological differences in hepatitis B virus genotypes from patients with acute hepatitis B in Japan; https://cir.nii.ac.jp/crid/1361981469074183552; Natural History of Chronic Hepatitis B; https://cir.nii.ac.jp/crid/1361981469144415744; Frequency and risk factors of renal impairment during long‐term adefovir dipivoxil treatment in chronic hepatitis B patients; https://cir.nii.ac.jp/crid/1361981469368479872; Survival and prognostic indicators in hepatitis B surface antigen-positive cirrhosis of the liver; https://cir.nii.ac.jp/crid/1361981469401976064; Increased risk of adefovir resistance in patients with lamivudine‐resistant chronic hepatitis B after 48 weeks of adefovir dipivoxil monotherapy†; https://cir.nii.ac.jp/crid/1361981469442883840; Interferon and prevention of hepatocellular carcinoma in viral cirrhosis: an evidence-based approach; https://cir.nii.ac.jp/crid/1361981469464068480; Entecavir is an optional agent to prevent hepatitis B virus (HBV) reactivation: A review of 16 patients; https://cir.nii.ac.jp/crid/1361981469479239808; A controlled trial of interferon with or without prednisone priming for chronic hepatitis B; https://cir.nii.ac.jp/crid/1361981469656179968; Low-dose, titratable interferon alfa in decompensated liver disease caused by chronic infection with hepatitis B virus; https://cir.nii.ac.jp/crid/1361981469930423040; Comprehensive analysis of risk factors associating with Hepatitis B virus (HBV) reactivation in cancer patients undergoing cytotoxic chemotherapy; https://cir.nii.ac.jp/crid/1361981470152682112; Reactivation of Hepatitis B Virus After Steroid Treatment in Rheumatic Diseases; https://cir.nii.ac.jp/crid/1361981470244521600; Entecavir Treatment for Up to 5 Years in Patients With Hepatitis B E Antigen–Positive Chronic Hepatitis B; https://cir.nii.ac.jp/crid/1361981470267574784; Peginterferon Alfa-2a, Lamivudine, and the Combination for HBeAg-Positive Chronic Hepatitis B; https://cir.nii.ac.jp/crid/1361981470478807936; Clonal Analysis of the Quasispecies of Antiviral-Resistant HBV Genomes in Patients with Entecavir Resistance during Rescue Treatment and Successful Treatment of Entecavir Resistance with Tenofovir; https://cir.nii.ac.jp/crid/1361981470782351872; Neurobehavioral Effects of Interferon-α in Cancer Patients Phenomenology and Paroxetine Responsiveness of Symptom Dimensions; https://cir.nii.ac.jp/crid/1361981470959241088; Hepatocellular carcinoma: the point of view of the hepatitis B virus; https://cir.nii.ac.jp/crid/1361981471153972480; Mutations of the core promoter and response to interferon treatment in chronic replicative hepatitis B; https://cir.nii.ac.jp/crid/1362262943308362624; Predicting response to peginterferon α-2a, lamivudine and the two combined for HBeAg-negative chronic hepatitis B; https://cir.nii.ac.jp/crid/1362262943446855296; Prophylaxis against hepatitis B recurrence following liver transplantation using combination lamivudine and hepatitis B immune globulin; https://cir.nii.ac.jp/crid/1362262943504364416; The Natural History of Asymptomatic Hepatitis B Surface Antigen Carriers; https://cir.nii.ac.jp/crid/1362262943647106944; Reverse seroconversion of hepatitis B virus after allogeneic hematopoietic stem cell transplantation in the absence of chronic graft-versus-host disease; https://cir.nii.ac.jp/crid/1362262943723140992; Long-term efficacy and safety of adefovir dipivoxil for the treatment of hepatitis B e antigen–positive chronic hepatitis B; https://cir.nii.ac.jp/crid/1362262944059414272; The polymerase L528M mutation cooperates with nucleotide binding-site mutations, increasing hepatitis B virus replication and drug resistance; https://cir.nii.ac.jp/crid/1362262944417920000; Peginterferon α‐2a (40 kDa): an advance in the treatment of hepatitis B e antigen‐positive chronic hepatitis B; https://cir.nii.ac.jp/crid/1362262944496558592; DNA-dependent activator of interferon-regulatory factors inhibits hepatitis B virus replication; https://cir.nii.ac.jp/crid/1362262944741879552; Long-Term Results With Interferon Therapy in Chronic Type B Hepatitis: A Prospective Randomized Trial; https://cir.nii.ac.jp/crid/1362262944967349120; HBV reactivation after kidney transplantation; https://cir.nii.ac.jp/crid/1362262945095635328; Recombinant α2c-interferon therapy in fulminant viral hepatitis; https://cir.nii.ac.jp/crid/1362262945158496640; A One-Year Trial of Lamivudine for Chronic Hepatitis B; https://cir.nii.ac.jp/crid/1362262945246144768; TRANSMISSION OF HEPATITIS B VIRUS FROM HEPATITIS B CORE ANTIBODY-POSITIVE DONORS IN LIVING RELATED LIVER TRANSPLANTS; https://cir.nii.ac.jp/crid/1362262945375677696; Meta-analysis: the effect of interferon on development of hepatocellular carcinoma in patients with chronic hepatitis B virus infection; https://cir.nii.ac.jp/crid/1362262945522443904; Viruses and Interferons; https://cir.nii.ac.jp/crid/1362262945664781952; Epidemiologic and virologic characteristics of hepatitis B virus genotype B having the recombination with genotype C; https://cir.nii.ac.jp/crid/1362262946178437120; Early is superior to deferred preemptive lamivudine therapy for hepatitis B patients undergoing chemotherapy; https://cir.nii.ac.jp/crid/1362262946285996288; Entecavir versus Lamivudine for Patients with HBeAg-Negative Chronic Hepatitis B; https://cir.nii.ac.jp/crid/1362262946294234752; Hepatotoxicity of antiretrovirals: Incidence, mechanisms and management; https://cir.nii.ac.jp/crid/1362544418289970944; Serologic and Clinical Outcomes of 1536 Alaska Natives Chronically Infected with Hepatitis B Virus; https://cir.nii.ac.jp/crid/1362544418545982592; Long–Term Beneficial Effect of Interferon Therapy in Patients With Chronic Hepatitis B Virus Infection; https://cir.nii.ac.jp/crid/1362544418733948672; HOW CELLS RESPOND TO INTERFERONS; https://cir.nii.ac.jp/crid/1362544418770474624; Fatal hepatitis B virus reactivation by an escape mutant following rituximab therapy; https://cir.nii.ac.jp/crid/1362544418835120000; Low risk of adefovir resistance in lamivudine-resistant chronic hepatitis B patients treated with adefovir plus lamivudine combination therapy: Two-year follow-up; https://cir.nii.ac.jp/crid/1362544418999024000; Risk Factors for Early-Onset and Late-Onset Hepatocellular Carcinoma in Asian Immigrants With Hepatitis B in the United States; https://cir.nii.ac.jp/crid/1362544419118896768; Successful treatment of an entecavir‐resistant hepatitis B virus variant; https://cir.nii.ac.jp/crid/1362544419163194112; Development of fulminant hepatitis B (precore variant mutant type) after the discontinuation of low-dose methotrexate therapy in a rheumatoid arthritis patient; https://cir.nii.ac.jp/crid/1362544419292936576; Long-term continuous entecavir therapy in nucleos(t)ide-naïve chronic hepatitis B patients; https://cir.nii.ac.jp/crid/1362544419369341696; Correlation between serum hepatitis B virus core‐related antigen and intrahepatic covalently closed circular DNA in chronic hepatitis B patients; https://cir.nii.ac.jp/crid/1362544419430145536; Shorter durations and lower doses of peginterferon alfa-2a are associated with inferior hepatitis B e antigen seroconversion rates in hepatitis B virus genotypes B or C; https://cir.nii.ac.jp/crid/1362544419471776768; Interferon alfa for patients with clinically apparent cirrhosis due to chronic hepatitis B; https://cir.nii.ac.jp/crid/1362544419637278208; Efficacy of entecavir treatment for lamivudine‐resistant hepatitis B over 3 years: Histological improvement or entecavir resistance?; https://cir.nii.ac.jp/crid/1362544419738589056; Clinical and Histological Events Preceding Hepatitis B e Antigen Seroconversion in Chronic Type B Hepatitis; https://cir.nii.ac.jp/crid/1362544419839767680; Effect of Alpha-Interferon Treatment in Patients with Hepatitis B e Antigen-Positive Chronic Hepatitis B; https://cir.nii.ac.jp/crid/1362544420058017152; Spontaneous reactivation of chronic hepatitis B virus infection; https://cir.nii.ac.jp/crid/1362544420073041664; Hepatitis B Virus Genotype and DNA Level and Hepatocellular Carcinoma: A Prospective Study in Men; https://cir.nii.ac.jp/crid/1362544420241549952; Hepatitis B genotypes and the response to interferon therapy; https://cir.nii.ac.jp/crid/1362544420246413184; Hepatitis B Virus Resistance to Nucleos(t)ide Analogues; https://cir.nii.ac.jp/crid/1362544420283809408; Ymdd Motif in Hepatitis B Virus Dna Polymerase Influences on Replication and Lamivudine Resistance: A Study By In Vitro Full–Length Viral Dna Transfection; https://cir.nii.ac.jp/crid/1362544420698668544; A Dominant Hepatitis B Virus Population Defective in Virus Secretion Because of Several S–Gene Mutations From A Patient With Fulminant Hepatitis; https://cir.nii.ac.jp/crid/1362544420724216704; Lamivudine treatment in patients with severely decompensated cirrhosis due to replicating hepatitis B infection; https://cir.nii.ac.jp/crid/1362544420840556416; Clinical course of patients with chronic hepatitis B with viral breakthrough during long-term lamivudine treatment; https://cir.nii.ac.jp/crid/1362544420847227776; Add-on combination therapy with adefovir dipivoxil induces renal impairment in patients with lamivudine-refractory hepatitis B virus; https://cir.nii.ac.jp/crid/1362544420874444032; Tenofovir Improves the Outcome in Patients with Spontaneous Reactivation of Hepatitis B Presenting as Acute-On-Chronic Liver Failure §Δ; https://cir.nii.ac.jp/crid/1362544421000344960; Reactivation of hepatitis B virus replication in patients receiving cytotoxic therapy; https://cir.nii.ac.jp/crid/1362825893477460736; HBsAg Seroclearance in Chronic Hepatitis B in Asian Patients: Replicative Level and Risk of Hepatocellular Carcinoma; https://cir.nii.ac.jp/crid/1362825893775818624; Sustained HBeAg and HBsAg Loss After Long-term Follow-up of HBeAg-Positive Patients Treated With Peginterferon α-2b; https://cir.nii.ac.jp/crid/1362825893835679616; The use of lamivudine for patients with acute hepatitis B (a series of cases); https://cir.nii.ac.jp/crid/1362825894061988864; Clinical, Virologic and Histologic Outcome Following Seroconversion From Hbeag to Anti–Hbe in Chronic Hepatitis Type B; https://cir.nii.ac.jp/crid/1362825894072077952; 15 BASELINE HBsAg LEVEL PREDICT HBsAg LOSS IN CHRONIC HEPATITIS B PATIENTS TREATED WITH A COMBINATION OF PEGINTERFERON ALFA-2A AND ADEFOVIR: AN INTERIM ANALYSIS; https://cir.nii.ac.jp/crid/1362825894091271168; Hepatitis B Core-Related Antigen Assay Is Useful for Monitoring the Antiviral Effects of Nucleoside Analogue Therapy; https://cir.nii.ac.jp/crid/1362825894307470464; Interferon and cyclosporin A in the treatment of fulminant viral hepatitis; https://cir.nii.ac.jp/crid/1362825894312713856; Long‐term outcomes of add‐on adefovir dipivoxil therapy to ongoing lamivudine in patients with lamivudine‐resistant chronic hepatitis B; https://cir.nii.ac.jp/crid/1362825894320542720; The neuroimmunology of stress and depression; https://cir.nii.ac.jp/crid/1362825894669784064; Redevelopment of Hepatitis B Surface Antigen After Renal Transplantation; https://cir.nii.ac.jp/crid/1362825894776300800; Three Years of Continuous Entecavir Therapy in Treatment-Naïve Chronic Hepatitis B Patients: VIRAL Suppression, Viral Resistance, and Clinical Safety; https://cir.nii.ac.jp/crid/1362825894853927040; Prevalence of hepatitis B virus infection in Japanese patients with HIV; https://cir.nii.ac.jp/crid/1362825895306972800; Quantitative serum HBsAg and HBeAg are strong predictors of sustained HBeAg seroconversion to pegylated interferon alfa‐2b in HBeAg‐positive patients; https://cir.nii.ac.jp/crid/1362825895462672768; Clinical evaluation of a new enzyme immunoassay for hepatitis B virus core‐related antigen; a marker distinct from viral DNA for monitoring lamivudine treatment; https://cir.nii.ac.jp/crid/1362825895519109760; Entecavir therapy for lamivudine‐refractory chronic hepatitis B; https://cir.nii.ac.jp/crid/1362825895677896576; Hepatitis B virus and hepatitis B-related viral infection in renal transplant recipients; https://cir.nii.ac.jp/crid/1362825895900696448; PLACEBO-CONTROLLED TRIAL OF RECOMBINANT α2-INTERFERON IN CHINESE HBsAg-CARRIER CHILDREN; https://cir.nii.ac.jp/crid/1362825896128269440; Relapse of hepatitis B in HBeAg-negative chronic hepatitis B patients who discontinued successful entecavir treatment: The case for continuous antiviral therapy; https://cir.nii.ac.jp/crid/1362825896158948992; Hepatitis E Virus and Chronic Hepatitis in Organ-Transplant Recipients; https://cir.nii.ac.jp/crid/1362825896238447104; Fatal Reactivation of Precore Mutant Hepatitis B Virus Associated with Fibrosing Cholestatic Hepatitis after Bone Marrow Transplantation; https://cir.nii.ac.jp/crid/1362825896272857472; Transient elastography and biomarkers for liver fibrosis assessment and follow-up of inactive hepatitis B carriers; https://cir.nii.ac.jp/crid/1362825896312907264; Fibrosis score consisting of four serum markers successfully predicts pathological fibrotic stages of chronic hepatitis <scp>B</scp>; https://cir.nii.ac.jp/crid/1363107368366859008; Adefovir Dipivoxil for Treatment of Breakthrough Hepatitis Caused by Lamivudine-Resistant Mutants of Hepatitis B Virus; https://cir.nii.ac.jp/crid/1363107368550282496; T1764G1766 core promoter double mutants are restricted to Hepatitis B virus strains with an A1757 and are common in genotype D; https://cir.nii.ac.jp/crid/1363107368675758208; Risk of selecting K65R in antiretroviral-naive HIV-infected individuals with chronic hepatitis B treated with adefovir; https://cir.nii.ac.jp/crid/1363107368713662336; Interferon therapy in HBeAg positive chronic hepatitis reduces progression to cirrhosis and hepatocellular carcinoma; https://cir.nii.ac.jp/crid/1363107368875478016; Intrahepatic response markers in chronic hepatitis B patients treated with peginterferon alpha‐2a and adefovir; https://cir.nii.ac.jp/crid/1363107368917157248; Acute Exacerbation of Chronic Hepatitis B Virus Infection After Withdrawal of Lamivudine Therapy; https://cir.nii.ac.jp/crid/1363107369320635648; Frequency of hepatitis B virus reactivation in cancer patients undergoing cytotoxic chemotherapy: A prospective study of 626 patients with identification of risk factors; https://cir.nii.ac.jp/crid/1363107369564771712; Efficacy of switching to entecavir monotherapy in Japanese lamivudine‐pretreated patients; https://cir.nii.ac.jp/crid/1363107369661404032; The Influence of Human Immunodeficiency Virus Type 1 Infection on the Development of the Hepatitis B Virus Carrier State; https://cir.nii.ac.jp/crid/1363107370037416320; Nomograms for Risk of Hepatocellular Carcinoma in Patients With Chronic Hepatitis B Virus Infection; https://cir.nii.ac.jp/crid/1363107370146067072; Entecavir Therapy for up to 96 Weeks in Patients With HBeAg-Positive Chronic Hepatitis B; https://cir.nii.ac.jp/crid/1363107370151989632; Meta‐analysis: treatment of hepatitis B infection reduces risk of hepatocellular carcinoma; https://cir.nii.ac.jp/crid/1363107370339349504; Mutations associated with the therapeutic efficacy of adefovir dipivoxil added to lamivudine in patients resistant to lamivudine with type B chronic hepatitis; https://cir.nii.ac.jp/crid/1363107370410901376; Entecavir treatment for chronic hepatitis B: Adaptation is not needed for the majority of naïve patients with a partial virological response; https://cir.nii.ac.jp/crid/1363107370588328320; Neutropenia during combination therapy of interferon alfa and ribavirin for chronic hepatitis C; https://cir.nii.ac.jp/crid/1363107370605359104; Determinants of early mortality in patients with decompensated chronic hepatitis B treated with antiviral therapy; https://cir.nii.ac.jp/crid/1363107370664646400; Liver grafts from anti-hepatitis B core positive donors: A systematic review; https://cir.nii.ac.jp/crid/1363107370706162176; Susceptibility of lamivudine-resistant hepatitis B virus to other reverse transcriptase inhibitors; https://cir.nii.ac.jp/crid/1363107370763247360; Interferon therapy in chronic hepatitis B reduces progression to cirrhosis and hepatocellular carcinoma: a meta‐analysis; https://cir.nii.ac.jp/crid/1363107370779885184; Efficacy of entecavir in treatment-naïve patients with hepatitis B virus-related decompensated cirrhosis; https://cir.nii.ac.jp/crid/1363107371232092928; Serum hepatitis B virus DNA levels and liver histology in inactive HBsAg carriers; https://cir.nii.ac.jp/crid/1363107371377652736; Systematic Review: The Effect of Preventive Lamivudine on Hepatitis B Reactivation during Chemotherapy; https://cir.nii.ac.jp/crid/1363388843277841280; Long‐term follow‐up of chronic hepatitis B after the emergence of mutations in the hepatitis B virus polymerase region; https://cir.nii.ac.jp/crid/1363388843376633472; Hepatitis B-Associated Acute Liver Failure: Immediate Treatment with Entecavir Inhibits Hepatitis B Virus Replication and Potentially Its Sequelae; https://cir.nii.ac.jp/crid/1363388843591353984; Attempted treatment of fulminant viral hepatitis with human fibroblast interferon; https://cir.nii.ac.jp/crid/1363388843768350208; Long-term clinical and histological outcomes in patients with spontaneous hepatitis B surface antigen seroclearance; https://cir.nii.ac.jp/crid/1363388843801677568; Chronic hepatitis B virus infection acquired in childhood: special emphasis on prognostic and therapeutic implication of delayed HBeAg seroconversion; https://cir.nii.ac.jp/crid/1363388843950715520; Diagnostic criteria of acute liver failure: A report by the Intractable Hepato‐Biliary Diseases Study Group of Japan; https://cir.nii.ac.jp/crid/1363388843968182912; Family history influences the early onset of hepatocellular carcinoma; https://cir.nii.ac.jp/crid/1363388844800075520; Long-term safety of lamivudine treatment in patients with chronic hepatitis B; https://cir.nii.ac.jp/crid/1363388844843001728; The HBV Drug Entecavir — Effects on HIV-1 Replication and Resistance; https://cir.nii.ac.jp/crid/1363388845054790912; Fanconi's Syndrome Associated with Prolonged Adefovir Dipivoxil Therapy in a Hepatitis B Virus Patient; https://cir.nii.ac.jp/crid/1363388845421927936; Viral genotypes and response to interferon in patients with acute prolonged hepatitis B virus infection of adulthood in Japan; https://cir.nii.ac.jp/crid/1363388845699549440; Efficacy and safety of entecavir versus adefovir in chronic hepatitis B patients with hepatic decompensation: A randomized, open-label study; https://cir.nii.ac.jp/crid/1363388846226485760; Peginterferon alpha‐2b is safe and effective in HBeAg‐positive chronic hepatitis B patients with advanced fibrosis† ‡ §; https://cir.nii.ac.jp/crid/1363670318326908416; Long-term follow-up of patients with anti-HBe/HBV DNA-positive chronic hepatitis B treated for 12 months with lamivudine; https://cir.nii.ac.jp/crid/1363670318479109376; Entecavir treatment in patients with severe acute exacerbation of chronic hepatitis B; https://cir.nii.ac.jp/crid/1363670318510868736; Lamivudine as Initial Treatment for Chronic Hepatitis B in the United States; https://cir.nii.ac.jp/crid/1363670318609076480; A Randomized Controlled Trial of Lymphoblastoid Interferon–α in Patients With Chronic Hepatitis B Lacking Hbeag; https://cir.nii.ac.jp/crid/1363670318623643392; Sequential treatment with lamivudine and interferon monotherapies in patients with chronic hepatitis B not responding to interferon alone: Results of a pilot study; https://cir.nii.ac.jp/crid/1363670318720292480; Efficacy of Lamivudine in Patients With Hepatitis B E Antigen-Negative/Hepatitis B Virus Dna-Positive (Precore Mutant) Chronic Hepatitis Befficacy of Lamivudine in Patients With Hepatitis B E Antigen-Negative/Hepatitis B Virus Dna-Positive (Precore Mutant) Chronic Hepatitis Befficacy of Lamivudine in Patients With Hepatitis B E Antigen-Negative/Hepatitis B Virus Dna-Positive (Precore Mutant) Chronic Hepatitis Befficacy of Lamivudine in Patients With Hepatitis B E Antigen-Negative/Hepatitis B Virus Dna-Positive (Precore Mutant) Chronic Hepatitis Bb; https://cir.nii.ac.jp/crid/1363670318971810176; Long–Term Suppression of Hepatitis B E Antigen–Negative Chronic Hepatitis B by 24–Month Interferon Therapy; https://cir.nii.ac.jp/crid/1363670319024315264; Interferon alfa-2b treatment of HBeAg negative/serum HBV DNA positive chronic active hepatitis type B; https://cir.nii.ac.jp/crid/1363670319335575168; Hepatitis B e Antigen-Negative Chronic Hepatitis B: Natural History and Treatment; https://cir.nii.ac.jp/crid/1363670319449500544; Serum HBsAg quantification to predict response to peginterferon therapy of e antigen positive chronic hepatitis B; https://cir.nii.ac.jp/crid/1363670319523929728; Entecavir resistance is rare in nucleoside naïve patients with hepatitis B; https://cir.nii.ac.jp/crid/1363670319693441408; Distinct geographic distributions of hepatitis B virus genotypes in patients with acute infection in Japan; https://cir.nii.ac.jp/crid/1363670319726192640; Carriers of Inactive Hepatitis B Virus Are Still at Risk for Hepatocellular Carcinoma and Liver-Related Death; https://cir.nii.ac.jp/crid/1363670319812668032; Current therapy for hepatitis C or D or immunodeficiency virus concurrent infection with chronic hepatitis B; https://cir.nii.ac.jp/crid/1363670319878136192; Adefovir plus lamivudine are more effective than adefovir alone in lamivudine‐resistant HBeAg^‐ chronic hepatitis B patients: A 4‐year study; https://cir.nii.ac.jp/crid/1363670320071691904; Beneficial Effects of Short-Term Lamivudine Treatment for de novo Hepatitis B Virus Reactivation After Liver Transplantation; https://cir.nii.ac.jp/crid/1363670320095960576; Fibrosing cholestatic hepatitis in a hepatitis B surface antigen carrier after renal transplantation; https://cir.nii.ac.jp/crid/1363670320220605824; Long-Term Entecavir Therapy Results in the Reversal of Fibrosis/Cirrhosis and Continued Histological Improvement in Patients with Chronic Hepatitis B†,‡; https://cir.nii.ac.jp/crid/1363670320240077696; Tailored regimen of interferon alpha for HBeAg‐positive chronic hepatitis B: a prospective controlled study; https://cir.nii.ac.jp/crid/1363670320381051520; Efficacy and Safety of Entecavir and/or Tenofovir for Prophylaxis and Treatment of Hepatitis B Recurrence Post–Liver Transplant; https://cir.nii.ac.jp/crid/1363670320531792768; Adefovir Dipivoxil for the Treatment of Hepatitis B e Antigen–Negative Chronic Hepatitis B; https://cir.nii.ac.jp/crid/1363670320557349376; Clinical features of hepatitis B virus genotype A in Japanese patients; https://cir.nii.ac.jp/crid/1363670320647080320; Effect of interferon-α on progression of cirrhosis to hepatocellular carcinoma: a retrospective cohort study; https://cir.nii.ac.jp/crid/1363670320679532928; Reactivation of DNA viruses in association with histone deacetylase inhibitor therapy: a case series report; https://cir.nii.ac.jp/crid/1363670320707551232; Entecavir to treat severe acute hepatitis B; https://cir.nii.ac.jp/crid/1363670320770888704; Initial viral response is the most powerful predictor of the emergence of YMDD mutant virus in chronic hepatitis B patients treated with lamivudine; https://cir.nii.ac.jp/crid/1363670320826618112; Follow-up and indications for liver biopsy in HBeAg-negative chronic hepatitis B virus infection with persistently normal ALT: A systematic review; https://cir.nii.ac.jp/crid/1363670320993869824; Long-term entecavir treatment reduces hepatocellular carcinoma incidence in patients with hepatitis B virus infection; https://cir.nii.ac.jp/crid/1363670320995969536; ‘e’ Antigen defective hepatitis B virus and course of chronic infection; https://cir.nii.ac.jp/crid/1363670321169133696; Incidence, determinants and significance of delayed clearance of serum HBsAg in chronic hepatitis B virus infection: A prospective study; https://cir.nii.ac.jp/crid/1363951793472289920; Acute exacerbation in chronic type B hepatitis: Comparison between HBeAg and antibody-positive patients; https://cir.nii.ac.jp/crid/1363951793541761920; Comparison of long‐term effects of lymphoblastoid interferon alpha and recombinant interferon alpha‐2a therapy in patients with chronic hepatitis B; https://cir.nii.ac.jp/crid/1363951794066370560; Preemptive use of lamivudine reduces hepatitis B exacerbation after allogeneic hematopoietic cell transplantation; https://cir.nii.ac.jp/crid/1363951794119795968; Early on‐treatment prediction of response to peginterferon alfa‐2a for HBeAg‐negative chronic hepatitis B using HBsAg and HBV DNA levels†; https://cir.nii.ac.jp/crid/1363951794146051712; Clinical Emergence of Entecavir-Resistant Hepatitis B Virus Requires Additional Substitutions in Virus Already Resistant to Lamivudine; https://cir.nii.ac.jp/crid/1363951794295554176; Response to interferon alfa is hepatitis B virus genotype dependent: genotype A is more sensitive to interferon than genotype D; https://cir.nii.ac.jp/crid/1363951795006793984; Severe hepatitis related to chemotherapy in hepatitis B virus carriers with hematologic malignancies: Survey in Japan, 1987-1991; https://cir.nii.ac.jp/crid/1363951795160891904; Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures; https://cir.nii.ac.jp/crid/1363951795619936384; Natural history of chronic hepatitis B: Special emphasis on disease progression and prognostic factors; https://cir.nii.ac.jp/crid/1363951795911877760; Durability of lamivudine-induced HBeAg seroconversion for chronic hepatitis B patients with acute exacerbation; https://cir.nii.ac.jp/crid/1363951795990153216; A preS mutation isolated from a patient with chronic hepatitis B infection leads to virus retention and misassembly; https://cir.nii.ac.jp/crid/1363951796033067008; LONG-TERM FOLLOW-UP IN A RANDOMISED CONTROLLED TRIAL OF RECOMBINANT α2-INTERFERON IN CHINESE PATIENTS WITH CHRONIC HEPATITIS B INFECTION; https://cir.nii.ac.jp/crid/1363951796119363968; Hepatitis B e Antigen and the Risk of Hepatocellular Carcinoma; https://cir.nii.ac.jp/crid/1363951796257319296; Long‐term outcome of hepatitis B e antigen–negative hepatitis B surface antigen carriers in relation to changes of alanine aminotransferase levels over time†; https://cir.nii.ac.jp/crid/1364233268287514880; Clinical and virological features of non-breakthrough and severe exacerbation due to lamivudine-resistant hepatitis B virus mutants; https://cir.nii.ac.jp/crid/1364233268440579072; Efficacy and safety of entecavir in nucleoside‐naive, chronic hepatitis B patients: Phase II clinical study in Japan; https://cir.nii.ac.jp/crid/1364233268672003456; Effects of extended lamivudine therapy in Asian patients with chronic hepatitis B; https://cir.nii.ac.jp/crid/1364233268721062272; Lamivudine for Patients with Chronic Hepatitis B and Advanced Liver Disease; https://cir.nii.ac.jp/crid/1364233268778503680; Host-independent evolution and a genetic classification of the hepadnavirus family based on nucleotide sequences.; https://cir.nii.ac.jp/crid/1364233268805068672; High risk of hepatitis B‐virus reactivation after hematopoietic cell transplantation in hepatitis B core antibody‐positive patients; https://cir.nii.ac.jp/crid/1364233268879454720; 683 ON-TREATMENT HBSAG DECLINE IN HBEAG-NEGATIVE PATIENTS AS A PREDICTOR OF RESPONSE TO PEGINTERFERON ALFA-2A (40KD) THERAPY 3 YEARS POST-TREATMENT: POTENTIAL FOR RESPONSE-GUIDED THERAPY; https://cir.nii.ac.jp/crid/1364233269148581888; Lamivudine therapy for chronic hepatitis B: A six-month randomized dose- ranging study; https://cir.nii.ac.jp/crid/1364233269280519424; Pretherapy alanine transaminase level as a determinant for hepatitis B e antigen seroconversion during lamivudine therapy in patients with chronic hepatitis B; https://cir.nii.ac.jp/crid/1364233269583957504; The predictive value of liver fibrosis in determining the effectiveness of interferon and lamivudine therapies for chronic hepatitis B; https://cir.nii.ac.jp/crid/1364233269756015104; High rates of HBsAg seroconversion in HBeAg-positive chronic hepatitis B patients responding to interferon: A long-term follow-up study; https://cir.nii.ac.jp/crid/1364233269880197120; Natural History of Chronic Hepatitis B Virus Infection: What We Knew in 1981 and What We Know in 2005; https://cir.nii.ac.jp/crid/1364233270006223360; The clinical significance of persistently normal ALT in chronic hepatitis B infection; https://cir.nii.ac.jp/crid/1364233270137995776; Adefovir Dipivoxil for the Treatment of Hepatitis B e Antigen–Positive Chronic Hepatitis B; https://cir.nii.ac.jp/crid/1364233270572938752; Full-Genome Nucleotide Sequence of a Hepatitis E Virus Strain That May Be Indigenous to Japan; https://cir.nii.ac.jp/crid/1364233270753102848; Prospective Nationwide Observational Study of Hepatitis B Virus (HBV) DNA Monitoring and Preemptive Antiviral Therapy for HBV Reactivation in Patients with B-Cell Non-Hodgkin Lymphoma Following Rituximab Containing Chemotherapy: Results of Interim Analysis.; https://cir.nii.ac.jp/crid/1364233270850420608; Hepatitis B Reactivation in a Multiple Myeloma Patient with Resolved Hepatitis B Infection during Bortezomib Therapy : Case Report; https://cir.nii.ac.jp/crid/1390001204704854656; Lamivudine Treatment Improves the Prognosis of Fulminant Hepatitis B; https://cir.nii.ac.jp/crid/1390001204870909184
• Data Provider (Database): 国立情報学研究所 : CiNii Research; https://cir.nii.ac.jp/
• Original Data Provider (Database): Japan Link Center; https://japanlinkcenter.org/top; 雑誌記事索引データベース; https://ndlsearch.ndl.go.jp; Crossref; https://www.crossref.org; CiNii Articles; 学術機関リポジトリデータベース; https://irdb.nii.ac.jp
• Bibliographic ID (NDL): 024632171; http://id.ndl.go.jp/bib/024632171; 024632149; http://id.ndl.go.jp/bib/024632149
• NAID: 10031183497; 10031183496